To include your compound in the COVID-19 Resource Center, submit it here.

Array rises on triplet response data in pretreated mCRC

Array BioPharma Inc. (NASDAQ:ARRY) gained $2.42 (19%) to $15.56 Monday after reporting updated response data for a combination regimen of encorafenib (LGX818), binimetinib (MEK162)

Read the full 241 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE